News and Trends 23 Nov 2022
FDA approves CSL gene therapy for hemophilia B
CSL has revealed that the U.S. Food and Drug Administration (FDA) has approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX…
